IB0%'3WP<DP2*AFC-D?^YM$'IFX2&)
SYSTEM PROCESSING...
IB0%'3WP<DP2*AFC-D?^YM$'IFX2&)
SYSTEM PROCESSING...
Posted: 2025-04-24 05:08:01 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-24 05:08:45 UTC
Verified By
Rollup News
A new State-of-the-Art review published in the European Heart Journal discusses transthyretin amyloid cardiomyopathy as a paradigm for advancing precision medicine.
Transthyretin amyloid cardiomyopathy
Precision medicine
New specific therapies
Advancements in imaging techniques
Initial therapy according to patient’s profile
Assessing response to therapy
Switching from one agent to another
Deprescribing treatment
Long-term safety of TTR depletion
Treatment of pre-symptomatic patients and ATTRv gene carriers